Investing.com - Financial Markets Worldwide

Alembic Pharmaceuticals Ltd (ALEM)

NSE
Symbol
Exchange
Currency
ALEM·NSE·INR
ALEM·BSE·INR
Currency in INR
959.65
+0.60(+0.06%)
Real-time Data·

ALEM Financial Summary

Key Ratios

P/E Ratio32.15
Price/Book3.86
Debt / Equity24.23%
Return on Equity11.63%
Dividend Yield1.15%
EBITDA9.89B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa53,931.353,057.956,526.262,286.366,720.7
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa40,529.238,075.838,778.444,325.147,913.1
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa12,968.45,874.74,377.86,607.47,298
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa11,4655,209.43,419.96,158.25,834.2
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa67,089.871,220.361,828.364,455.877,729.4
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa12,808.417,165.316,369.214,55024,123.4
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa50,669.752,375.543,704.748,18251,895.2
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa4,358.73-324.73504.462,198.24-7,272.16
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa14,633.85,523.57,239.58,032879.7
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-8,388.1-3,719.7-4,475.9-3,206.1-5,684.1
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-5,974.3-2,173.5-2,619.6-4,378.74,437.1
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa262.2-369.7143.9447.3-367.3
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 29.68%
Dividend Yield
1.15%
Industry Median 0.73%
Annualised payout
11.00
Paid annually
5-Years Growth
+9.46%
Growth Streak
Unlock

Analyst Ratings

7 Buy
4 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,029.91
(+7.32% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
8.00 / 9.00
Revenue / Forecast
17.70B / 15.41B
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Alembic Pharmaceuticals Ltd's earnings for the latest quarter?

The Alembic Pharmaceuticals Ltd EPS (TTM) is 29.68. Alembic Pharmaceuticals Ltd reported sales of 17,696.20, net income of 1,568.90, and EPS of 8.00 for the latest quarter.

What was Alembic Pharmaceuticals Ltd's net income for the latest quarter?

Alembic Pharmaceuticals Ltd's net income for the latest quarter was 1,568.90.

How did Alembic Pharmaceuticals Ltd's performance compare year-over-year in the latest quarter?

The company's revenue moved from 16,927.50 in the previous quarter to 17,696.20 in the latest quarter, and net income moved from 1,384.20 to 1,568.90 compared to the previous quarter.

What is Alembic Pharmaceuticals Ltd's net profit margin on a TTM basis?

Alembic Pharmaceuticals Ltd's trailing twelve months (TTM) net profit margin is 8.74%.

How does Alembic Pharmaceuticals Ltd's debt to equity ratio compare to industry standards?

Alembic Pharmaceuticals Ltd's total debt-to-equity ratio is 24.23%.

What is Alembic Pharmaceuticals Ltd's return on investment on a TTM basis?

Alembic Pharmaceuticals Ltd's trailing twelve months (TTM) return on investment (ROI) is 11.63%.

What were Alembic Pharmaceuticals Ltd's total assets and liabilities in the latest quarter?

As of the latest quarter, Alembic Pharmaceuticals Ltd reported total assets of 77,729.40 million and total liabilities of 24,123.40 million.

How has Alembic Pharmaceuticals Ltd's total revenue grown this year?

Alembic Pharmaceuticals Ltd's total revenue was 16,927.50 in the previous quarter and 17,696.20 in the latest quarter.

What is Alembic Pharmaceuticals Ltd's gross margin on a TTM basis?

Alembic Pharmaceuticals Ltd's trailing twelve months (TTM) gross margin is 71.81%.

What was Alembic Pharmaceuticals Ltd's revenue per share for the latest quarter?

Alembic Pharmaceuticals Ltd's revenue per share for the latest quarter was 298.95.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.